Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OriolaCHIX:ORIOLH 38 Cash-to-Debt is 1.45 as of Jun. 2026, which is 164% above its 10-year median of 0.55. GuruFocus rates CHIX:ORIOLH with a GF Score™ of 38/100 and a GF Value™ of €0.73. The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Oriola ranks better than 61.53% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Oriola's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.45.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Oriolacould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Oriola's Cash-to-Debt or its related term are showing as below:
CHIX:ORIOLh'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: 0.55 Max: 2.17
Current: 1.45
During the past 13 years, Oriola's highest Cash to Debt Ratio was 2.17. The lowest was 0.11. And the median was 0.55.
CHIX:ORIOLh's Cash-to-Debt is ranked better than 61.53% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 0.775
vs CHIX:ORIOLh: 1.45
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Oriola Cash-to-Debt Related Terms
Oriola Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Oriola's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Pharmaceutical Retailers subindustry, Oriola's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oriola Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Oriola's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Oriola's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oriola (CHIX:ORIOLH) has a Cash-to-Debt of 1.45 as of Jun. 2026. This is 164% above median its historical median of 0.55. Over the past decade, Oriola's Cash-to-Debt has ranged from 0.11 to 2.17. According to the industry distribution chart, Oriola ranks #257 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 38.5%.
Is Oriola's Cash-to-Debt too high?
Oriola's current Cash-to-Debt of 1.45 is 164% above median its 10-year median of 0.55. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 2.17. The Healthcare Providers & Services industry median Cash-to-Debt is 0.78. Oriola's value of 1.45 is 87.1% above this industry median. Based on the distribution chart, Oriola ranks #257 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Oriola has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Oriola's Cash-to-Debt compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Oriola ranks #257 out of 668 companies for Cash-to-Debt. This puts Oriola in the upper half of its industry. The industry median Cash-to-Debt is 0.78. Oriola's value of 1.45 is 87.1% above this benchmark. Historically, Oriola's own Cash-to-Debt has ranged from 0.11 to 2.17 over the past decade. While the company's 10-year median is 0.55 vs. the industry median of 0.78, Oriola has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.78, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oriola's current Cash-to-Debt of 1.45 is 87.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oriola's current Cash-to-Debt is 1.45, which is 164% above median its own 10-year median of 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oriola stock overvalued right now?
Oriola (CHIX:ORIOLH) has a current Cash-to-Debt of 1.45. The stock's GF Value™ is €0.73, compared to a current price of €0.94 — trading 28.5% above its estimated fair value. The current Cash-to-Debt is 1.45, which is 164% above median its 10-year median of 0.55 and 87.1% above the Healthcare Providers & Services industry median of 0.78. Oriola's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Oriola (CHIX:ORIOLH), the current Cash-to-Debt is 1.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oriola (CHIX:ORIOLH) Overvalued in 2026?
Based on GuruFocus' analysis, Oriola stock appears to be overvalued.
The current stock price of €0.94 is trading 28.5% above its estimated GF Value™ of €0.73.
Key valuation signals for CHIX:ORIOLH:
Cash-to-Debt: 1.45 (164% above median its 10-year median of 0.55)
GF Value™: €0.73 vs. price of €0.94 (28.5% above fair value)
Industry Position: 87.1% above the Healthcare Providers & Services median (#257 of 668)
No single metric tells the full story. See the CHIX:ORIOLH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oriola Corp is a health and wellbeing company operating in Nordic countries. It offers services such as the distribution of pharmaceuticals and other health and well-being products, services, and dose dispensing. Oriola's operations are divided into two segments which include distribution and wholesale. Geographically, the company operates in Sweden, Finland and other countries generating majority revenue from the region of Sweden.
38GF Score
Get the complete analysis for CHIX:ORIOLH
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ORIOLH has been successfully added to your 
